Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review
Autor: | Victoria Gil Martínez, Sonia Santander Ballestín, Ana Avedillo Salas |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
safety
0301 basic medicine medicine.medical_specialty ribavirin Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) efficacy MEDLINE Pharmaceutical Science Lopinavir/ritonavir remdesivir Review favipiravir Favipiravir arbidol 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pharmacy and materia medica umifenovir Drug Discovery medicine 030212 general & internal medicine Intensive care medicine Adverse effect treatment business.industry SARS-CoV-2 Ribavirin virus diseases COVID-19 Lopinavir lopinavir/ritonavir antiviral RS1-441 030104 developmental biology chemistry Molecular Medicine Medicine Ritonavir business medicine.drug |
Zdroj: | Pharmaceuticals, Vol 14, Iss 736, p 736 (2021) Pharmaceuticals |
ISSN: | 1424-8247 |
Popis: | Due to the lack of an etiologic treatment for SARS-CoV-2 and the difficulties involved in developing new drugs, some drugs already approved for other diseases or with efficacy against SARS and MERS, have been used in patients with COVID-19. This systematic review aims to summarize evidence on the efficacy and safety of five antivirals applied to patients with COVID-19, that have proven to be effective either in vitro studies or in studies on SARS-CoV and MERS.; An intensive search of different databases (Pub Med, WoS, MEDLINE and Cochrane COVID-19 Study Register) has been carried out until the end of April 2021. This systematic review has been conducted according to the PRISMA statement. From each of the included studies, the characteristics of the intervention and comparison groups, demographic data and results were extracted independently; Remdesivir is well tolerated and helps to accelerate clinical improvement but is ineffective in reducing mortality. Favipiravir is safe and shows promising results regarding symptom resolution but does not improve viral clearance. The use of lopinavir/ritonavir has been associated with an increased risk of gastrointestinal adverse events and it has not proven to be effective. No significant differences were observed between patients treated with ribavirin or umifenovir and their respective control groups; Remdesivir and favipiravir are well tolerated and effective in accelerating clinical improvement. This systematic review does not support the use of lopinavir/ritonavir, ribavirin and umifenovir in hospitalized patients with COVID-19. |
Databáze: | OpenAIRE |
Externí odkaz: |